542 related articles for article (PubMed ID: 31576784)
1. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Hwang J; Yokota T
Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
[TBL] [Abstract][Full Text] [Related]
2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
3. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Rodrigues M; Yokota T
Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
[TBL] [Abstract][Full Text] [Related]
4. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
5. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
[TBL] [Abstract][Full Text] [Related]
6. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
8. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.
Dzierlega K; Yokota T
Gene Ther; 2020 Sep; 27(9):407-416. PubMed ID: 32483212
[TBL] [Abstract][Full Text] [Related]
9. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
10. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
13. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
Niks EH; Aartsma-Rus A
Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy.
López-Martínez A; Soblechero-Martín P; Arechavala-Gomeza V
Methods Mol Biol; 2022; 2434():217-233. PubMed ID: 35213020
[TBL] [Abstract][Full Text] [Related]
15. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
16. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
[TBL] [Abstract][Full Text] [Related]
17. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
18. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
19. Golodirsen for Duchenne muscular dystrophy.
Anwar S; Yokota T
Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
[TBL] [Abstract][Full Text] [Related]
20. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]